Human lipoprotein lipase(LPL)ELISA Kit

Code CSB-E08493h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
lipoprotein lipase
Alternative Names
EC 3.1.1 ELISA Kit; EC ELISA Kit; HDLCQ11 ELISA Kit; LIPD ELISA Kit; LIPL_HUMAN ELISA Kit; Lipoprotein lipase ELISA Kit; LPL ELISA Kit; LPL protein ELISA Kit; MGC137861 ELISA Kit
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
31.25 pg/mL-2000 pg/mL
7.81 pg/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human LPL in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:100Average %90
Range %84-97
1:200Average %95
Range %89-99
1:400Average %99
Range %95-104
1:800Average %92
Range %88-95
The recovery of human LPL spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 8984-96
EDTA plasma (n=4)9389-98
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
20002.579 2.599 2.589 2.435
10002.264 2.215 2.240 2.086
5001.798 1.771 1.785 1.631
2501.369 1.370 1.370 1.216
1250.942 0.982 0.962 0.808
62.50.555 0.569 0.562 0.408
31.250.306 0.321 0.314 0.160
00.153 0.155 0.154  
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

This Human LPL ELISA Kit was designed for the quantitative measurement of Human LPL protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 31.25 pg/mL-2000 pg/mL and the sensitivity is 7.81 pg/mL .

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Key enzyme in triglyceride metabolism. Catalyzes the hydrolysis of triglycerides from circulating chylomicrons and very low density lipoproteins (VLDL), and thereby plays an important role in lipid clearance from the blood stream, lipid utilization and storage. Although it has both phospholipase and triglyceride lipase activities it is primarily a triglyceride lipase with low but detectable phospholipase activity. Mediates margination of triglyceride-rich lipoprotein particles in capillaries. Recruited to its site of action on the luminal surface of vascular endothelium by binding to GPIHBP1 and cell surface heparan sulfate proteoglycans.
Gene References into Functions
  1. LPL-mediated release of essential fatty acid DHA regulates hematopoietic stem progenitor cell expansion and definitive hematopoiesis PMID: 29615667
  2. the negatively charged IDR of GPIHBP1 traverses a vast space, facilitating capture of LPL by capillary endothelial cells and simultaneously contributing to GPIHBP1's ability to preserve LPL structure and activity. PMID: 29899144
  3. nder optimal conditions, the electrochemical DNA biosensor exhibited desirable performance for the determination of rs1801177 (of the lipoprotein lipase )with a wide linearity ranging from 10 fM to 10nM and a relatively low detection limit of 3.33 fM (S/N=3). PMID: 29175215
  4. A link between the expression of LPL in the tumor cells and a poor clinical outcome of patients suffering chronic lymphocytic leukemia has been established. (Review) PMID: 29206143
  5. Pvu II restriction fragment length polymorphism associated with an elevated risk of hypertriglyceridemia [meta-analysis] PMID: 28502159
  6. When her TG levels normalized after incidental use of prednisone, an autoimmune mechanism was suspected. Immunoblot analyses showed the presence of autoantibodies to LPL in the patient's plasma. Autoantibodies to LPL decreased by 37% while patient was on prednisone, and by 68% as she subsequently transitioned to hydroxychloroquine monotherapy PMID: 28916403
  7. Updated LPL structural models were generated by combining disulfide mapping, computational modeling, and data derived from single-molecule Forster resonance energy transfer. New computational suggest that LPL may dimerize using an interface that is different from the dimerization interface suggested by crystal packing contacts seen in structures of pancreatic lipase. PMID: 29303250
  8. This meta-analysis suggested that LPL HindIII variants were associated with a decreased risk of stroke in the Asian population, but not in the non-Asian population. PMID: 28687421
  9. LPL HindIII (+/-) and PvuII (+/-), but not the Ser447Ter, might significantly reduce the risk of ischemic stroke. PMID: 29718838
  10. apoC-III potently inhibits triglyceride hydrolysis when LPL is bound to GPIHBP1 PMID: 28694296
  11. The results of this meta-analysis suggested that the LPL S447X polymorphism is likely to be a protective factor in the development of hypertension. PMID: 28640651
  12. Sequence variation in Kuwaiti Arabs was compared to other populations and was found to be similar with regards to the number of SNPs, InDels and distribution of the number of variants across the LPL gene locus and minor allele frequency PMID: 29438437
  13. Regression analysis revealed significant risk for memory loss that are dependent on age and genetic variants like LPL. PMID: 28777751
  14. The findings in this study suggest that there is a poor concordance between apo E genotyping and lipoprotein electrophoresis in diagnosing dysbetalipoproteinemia. PMID: 28689531
  15. mutation of a conserved cysteine in GPIHBP1 abolishes the ability of GPIHBP1 to bind LPL PMID: 28476858
  16. ANGPTL8 has a functional LPL inhibitory motif, but only inhibits LPL and increases plasma TG levels in mice in the presence of ANGPTL3 PMID: 28413163
  17. The expression of COBLL1, LPL, and ZAP70 corresponded to patient prognosis and to IGHV mutational status, although not absolutely. When we combined all three markers together and performed the ROC analysis, AUC increased compared to the AUC of individual gene expression. PMID: 27185377
  18. heterozygous N291S mutation in the lipoprotein lipase gene impairs whole-body insulin sensitivity and affects a distinct set of plasma metabolites in humans PMID: 28502509
  19. The authors now show: (1) that ANGPTL4 inactivates LPL by catalyzing the unfolding of its hydrolase domain; (2) that binding to GPIHBP1 renders LPL largely refractory to this inhibition; and (3) that both the LU domain and the intrinsically disordered acidic domain of GPIHBP1 are required for this protective effect. PMID: 27929370
  20. Carrier status for the two common LPL variants: 447Ter (low TG/high HDL-C) and 291Ser (high TG/low HDL-C) was determined. Compared with the reference variant, the prevalence of metabolic syndrome was lower in carriers of the 447Ter variant (11.2% vs. 17.9%, P < 0.001) but with no difference in carriers of the 291Ser variant (18.4% vs. 16.5%, P = 0.59). PMID: 27676127
  21. A rare variant in APOC3(rs138326449) has been associated with triglyceride, very low-density lipoprotein, and high-density lipoprotein levels, as well as risk of coronary heart disease. Effects are unlikely to be solely predictable by the action of APOC3 through LPL. PMID: 27114411
  22. LPL gene polymorphisms are not genetic markers for the development of stroke in the Colombian sample used. PMID: 28293042
  23. Acute hypoxia strongly inhibits lipoprotein lipase activity in differentiated human preadipocytes. PMID: 27421877
  24. novel mutations cause type 1 hyperlipoproteinemia by inducing a loss or reduction in LPL secretion accompanied by a loss of LPL enzymatic activity PMID: 27578112
  25. LPL HindIII polymorphism was significantly associated with the risk of coronary artery disease (CAD); for Ser447X polymorphism, it was found that only XX genotype was significantly associated with CAD risk; PvuII polymorphism had no significant association with CAD risk; LPL HindIII polymorphism might serve as a potential biomarker for CAD risk PMID: 28275220
  26. Rare variants in LPL and a common variant in APOA5 were more commonly found in Thai subjects with severe hypertriglyceridemia PMID: 27206937
  27. apoC-I inhibited in situ LPL activity in adipocytes in both a concentration- and time-dependent manner. There was no change in postprandial WAT apoC-I secretion. WAT apoC-I secretion may inhibit WAT LPL activity and promote delayed chylomicron clearance in overweight and obese subjects PMID: 27040450
  28. isothermal titration calorimetry (ITC) can be used for quantitative measurements of LPL activity and interactions under in vivo-like conditions, for comparisons of the properties of plasma samples from patients and control subjects as substrates for LPL, as well as for testing of drug candidates developed with the aim to affect the LPL system. PMID: 27845686
  29. mAbs RE3 and RG3 bound with reduced affinity to a mutant GPIHBP1 containing an Ly6 domain mutation (W109S) that abolishes LPL binding. Immunohistochemistry studies with the GPIHBP1 mAbs revealed that human GPIHBP1 is expressed only in capillary endothelial cells. Finally, we created an ELISA that detects GPIHBP1 in human plasma. PMID: 27875259
  30. Iotansulin decreased LPL mRNA levels in HepG2 cells and this was associated with phosphorylation of AKT and nuclear export of FOXA2. PMID: 28126606
  31. The binding of both antibody 88B8 and GPIHBP1 to LPL depends on large segments of LPL's carboxyl-terminal domain. PMID: 27494936
  32. Loss of Lipoprotein Lipase is associated with Pancreatitis. PMID: 27412455
  33. In this study, most of the LPL gene variants were not significantly different in adolescents with normal and elevated triglceryide levels PMID: 28397436
  34. The data suggest the importance of C-mannosylation for LPL functions. PMID: 28327359
  35. The single nucleotide polymorphisms in lipoprotein lipase, ApoA5, and CETP were associated with serum triglycerides and HDL-cholesterol levels, but not with coronary artery disease in Pakistani population under study. PMID: 28143480
  36. An LPL structural model suggests that the LPL S447X truncation exposes residues implicated in LPL binding to lipoprotein binding uptake receptors, such as GPIHBP1. PMID: 27984852
  37. results confirm that LPL expression is a strong predictor of outcome in chronic lymphocytic leukemia, indicating a progressive course with poor survival PMID: 27757836
  38. Reduced LPL expression in placenta, limited increase in LPL level in maternal plasma, and abnormal lipid profiles were found in patients with intrahepatic cholestasis of pregnancy. PMID: 27400425
  39. The presence of rare damaging mutations in LPL was significantly associated with higher triglyceride levels and presence of coronary artery disease. PMID: 28267856
  40. Data show that polymorphisms of rs662799 and rs2266788 in APOA5 gene, rs320 in LPL gene and rs708272 in CETP gene had significant association with the effect of the lipid-lowering therapy via atorvastatin on ischemic stroke patients. PMID: 27415775
  41. NOTCH1 mutations are tightly associated with LPL gene expression. LPL expression is independently associated with poor outcome in CLL and can be measured as a categorical variable. PMID: 26558352
  42. Polymorphisms in the LPL gene are associated with increased risk of acute non-biliary pancreatitis. PMID: 27270932
  43. No significant increase of LPL activity was found at CM and VLDL overload after different kinds of food intake PMID: 27908779
  44. LPL and PLTP appear to be novel glioma-associated proteins and play a role in the progression of human glioma PMID: 27864281
  45. The acidic domain of GPIHBP1 stabilizes LPL catalytic activity by mitigating the global unfolding of LPL's catalytic domain. PMID: 26725083
  46. Chronic lymphocytic leukemia patients with high UGT2B17 and LPL expression have significantly reduced survival. PMID: 26589911
  47. Regulation of LPL by the miR-29, miR-1277 and miR-410 that is lost in presence of Hap4, a specific LPL TG-lowering haplotype. Consequently p.Ser474Ter association with TG concentration could be at least partially explained by its strong linkage disequilibrium with these functional 3'UTR SNPs. PMID: 26820803
  48. eleterious mutations associated with LPL deficiency PMID: 27055971
  49. In the present study, the D9N, N291S, and T495G polymorphisms of the LPL gene were not risk factors for the development of CVD. PMID: 26853140
  50. S447X polymorphism is associated with postprandial triacylglycerol and glucose. PMID: 26999119

Show More

Hide All

Involvement in disease
Lipoprotein lipase deficiency (LPL deficiency)
Subcellular Location
Cell membrane; Peripheral membrane protein; Extracellular side. Secreted. Secreted, extracellular space, extracellular matrix.
Protein Families
AB hydrolase superfamily, Lipase family
Tissue Specificity
Detected in blood plasma. Detected in milk (at protein level).
Database Links

HGNC: 6677

OMIM: 238600

KEGG: hsa:4023

STRING: 9606.ENSP00000309757

UniGene: Hs.180878

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1